Literature DB >> 9930313

FMEV vectors: both retroviral long terminal repeat and leader are important for high expression in transduced hematopoietic cells.

M Hildinger1, H G Eckert, A J Schilz, J John, W Ostertag, C Baum.   

Abstract

FMEV retroviral vectors combine the long terminal repeat of Friend mink cell focus-forming viruses with the 5' untranslated leader region of the murine embryonic stem cells virus. These modules were connected to achieve high transgene expression in hematopoietic progenitor and stem cells. Here, we report the cloning of safety-improved and versatile FMEV vectors allowing module-wise exchange of crucial elements for comparative studies. By transfer and expression of four different marker genes (neomycin phosphotransferase, lacZ, enhanced green fluorescent protein and truncated low affinity nerve growth factor receptor), we formally demonstrate that both the long terminal repeat and the leader contribute to the high expression of FMEV in transduced hematopoietic cells. Most prominent are the data recorded in the absence of selection in myelo-erythroid progenitor cells. Here, FMEV vectors mediate up to two orders of magnitude increased transgene expression levels when compared with vectors based on the Moloney murine leukemia virus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9930313     DOI: 10.1038/sj.gt.3300759

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  10 in total

1.  Design of 5' untranslated sequences in retroviral vectors developed for medical use.

Authors:  M Hildinger; K L Abel; W Ostertag; C Baum
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 2.  Hematopoietic stem cell engineering at a crossroads.

Authors:  Isabelle Rivière; Cynthia E Dunbar; Michel Sadelain
Journal:  Blood       Date:  2011-11-17       Impact factor: 22.113

3.  HOXB4 enforces equivalent fates of ES-cell-derived and adult hematopoietic cells.

Authors:  Sandra Pilat; Sebastian Carotta; Bernhard Schiedlmeier; Kenji Kamino; Andreas Mairhofer; Elke Will; Ute Modlich; Peter Steinlein; Wolfram Ostertag; Christopher Baum; Hartmut Beug; Hannes Klump
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-10       Impact factor: 11.205

Review 4.  Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases.

Authors:  David A Williams; Adrian J Thrasher
Journal:  Stem Cells Transl Med       Date:  2014-03-28       Impact factor: 6.940

5.  In vivo analysis of retroviral enhancer mutations in hematopoietic cells: SP1/EGR1 and ETS/GATA motifs contribute to long terminal repeat specificity.

Authors:  Anke Wahlers; Peter F Zipfel; Maike Schwieger; Wolfram Ostertag; Christopher Baum
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates.

Authors:  Brian C Beard; Grant D Trobridge; Christina Ironside; Jeannine S McCune; Jennifer E Adair; Hans-Peter Kiem
Journal:  J Clin Invest       Date:  2010-06-14       Impact factor: 14.808

7.  CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells.

Authors:  Thomas D Southgate; Owen J McGinn; Fernanda V Castro; Andrzej J Rutkowski; Mariam Al-Muftah; Georgi Marinov; Graeme J Smethurst; David Shaw; Christopher M Ward; Crispin J Miller; Peter L Stern
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

Review 8.  Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection.

Authors:  Michael D Milsom; David A Williams
Journal:  DNA Repair (Amst)       Date:  2007-05-07

9.  Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides.

Authors:  Marc Egelhofer; Gunda Brandenburg; Holger Martinius; Patricia Schult-Dietrich; Gregory Melikyan; Renate Kunert; Christopher Baum; Ingrid Choi; Alexander Alexandrov; Dorothee von Laer
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  Retroviral gene therapy in Germany with a view on previous experience and future perspectives.

Authors:  Michael A Morgan; Melanie Galla; Manuel Grez; Boris Fehse; Axel Schambach
Journal:  Gene Ther       Date:  2021-03-22       Impact factor: 5.250

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.